Clinical utility of chitotriosidase enzyme activity in nephropathic cystinosis

Mohamed A. Elmonem, Samuel H. Makar, Lambertus Van Den Heuvel, Hanan Abdelaziz, Safaa M. Abdelrahman, Xavier Bossuyt, Mirian C. Janssen, Elisabeth A.M. Cornelissen, Dirk J. Lefeber, Leo A.B. Joosten, Marwa M. Nabhan, Fanny O. Arcolino, Fayza A. Hassan, Héloïse P. Gaide Chevronnay, Neveen A. Soliman, Elena Levtchenko

Research output: Contribution to journalArticleAcademicpeer-review

24 Citations (Scopus)

Abstract

Background: Nephropathic cystinosis is an inherited autosomal recessive lysosomal storage disorder characterized by the pathological accumulation and crystallization of cystine inside different cell types. WBC cystine determination forms the basis for the diagnosis and therapeutic monitoring with the cystine depleting drug (cysteamine). The chitotriosidase enzyme is a human chitinase, produced by activated macrophages. Its elevation is documented in several lysosomal storage disorders. Although, about 6% of Caucasians have enzyme deficiency due to homozygosity of 24-bp duplication mutation in the chitotriosidase gene, it is currently established as a screening marker and therapeutic monitor for Gaucher's disease. Methods: Plasma chitotriosidase activity was measured in 45 cystinotic patients, and compared with 87 healthy controls and 54 renal disease patients with different degrees of renal failure (CKD1-5). Chitotriosidase levels were also correlated with WBC cystine in 32 treated patients. Furthermore, we incubated control human macrophages in-vitro with different concentrations of cystine crystals and monitored the response of tumor necrosis factor-alpha (TNF-α) and chitotriosidase activity. We also compared plasma chitotriosidase activity in cystinotic knocked-out (n = 10) versus wild-type mice (n = 10). Results: Plasma chitotriosidase activity in cystinotic patients (0-3880, median 163 nmol/ml/h) was significantly elevated compared to healthy controls (0-90, median 18 nmol/ml/h) and to CKD patients (0-321, median 52 nmol/ml/h), P < 0.001 for both groups. Controls with decreased renal function had mild to moderate chitotriosidase elevations; however, their levels were significantly lower than in cystinotic patients with comparable degree of renal insufficiency. Chitotriosidase activity positively correlated with WBC cystine content for patients on cysteamine therapy (r = 0.8), P < 0.001. In culture, human control macrophages engulfed cystine crystals and released TNF-α into culture supernatant in a crystal concentration dependent manner. Chitotriosidase activity was also significantly increased in macrophage supernatant and cell-lysate. Furthermore, chitotriosidase activity was significantly higher in cystinotic knocked-out than in the wild-type mice, P = 0.003. Conclusions: This study indicates that cystine crystals are potent activators of human macrophages and that chitotriosidase activity is a useful marker for this activation and a promising clinical biomarker and therapeutic monitor for nephropathic cystinosis.

Original languageEnglish
Article number155
JournalOrphanet Journal of Rare Diseases
Volume9
DOIs
Publication statusPublished - 2014
Externally publishedYes

Keywords

  • Chitotriosidase enzyme
  • Clinical screening
  • Cysteamine
  • Cystine crystals
  • Lysosomal storage disorders
  • Macrophage activation
  • Nephropathic cystinosis
  • Therapeutic monitoring

Cite this